Abstract
The extracellular matrix (ECM) is a complex of self assembled macromolecules. It is composed predominantly of collagens, non-collagenous glycoproteins, hyaluronan and proteoglycans. ECM is not only a scaffold for the cells; it serves also as a reservoir for growth factors and cytokines and modulates the cell activation status and turnover. ECM should be considered a dynamic network of molecules secreted by cells that in turn regulate cell behavior by modulating their proliferation and differentiation. The ECM provides structural strength to tissues, maintaining a complex architecture around the cells and the shape of organs. Various cell types secrete different matrix molecules and the nature and the amount of these molecules change during developmental age. Cartilage ECM is composed mainly of two components defining its mechano-physical properties: the collagenous network, responsible for the tensile strength of the cartilage matrix, and the proteoglycans (mainly aggrecan), responsible for the osmotic swelling and the elastic properties of the cartilage tissue. The conversion of cartilage into bone requires several processes that directly involve the different ECM components. Homeostasis of cartilage and bone is maintained by complex mechanisms controlling turnover and remodeling of ECM. In bone, as well as in cartilage, the ECM resident cells produce local factors, inflammatory mediators, and matrix-degrading enzymes. Turnover and degradation of normal and pathological matrices are dependent on the responses of the local cell to auto and paracrine anabolic and catabolic pathway.
Keywords: Extracellular matrix, cartilage, bone, collagen, proteoglycan, growth factor
Current Pharmaceutical Design
Title: Cartilage and Bone Extracellular Matrix
Volume: 15 Issue: 12
Author(s): Chiara Gentili and Ranieri Cancedda
Affiliation:
Keywords: Extracellular matrix, cartilage, bone, collagen, proteoglycan, growth factor
Abstract: The extracellular matrix (ECM) is a complex of self assembled macromolecules. It is composed predominantly of collagens, non-collagenous glycoproteins, hyaluronan and proteoglycans. ECM is not only a scaffold for the cells; it serves also as a reservoir for growth factors and cytokines and modulates the cell activation status and turnover. ECM should be considered a dynamic network of molecules secreted by cells that in turn regulate cell behavior by modulating their proliferation and differentiation. The ECM provides structural strength to tissues, maintaining a complex architecture around the cells and the shape of organs. Various cell types secrete different matrix molecules and the nature and the amount of these molecules change during developmental age. Cartilage ECM is composed mainly of two components defining its mechano-physical properties: the collagenous network, responsible for the tensile strength of the cartilage matrix, and the proteoglycans (mainly aggrecan), responsible for the osmotic swelling and the elastic properties of the cartilage tissue. The conversion of cartilage into bone requires several processes that directly involve the different ECM components. Homeostasis of cartilage and bone is maintained by complex mechanisms controlling turnover and remodeling of ECM. In bone, as well as in cartilage, the ECM resident cells produce local factors, inflammatory mediators, and matrix-degrading enzymes. Turnover and degradation of normal and pathological matrices are dependent on the responses of the local cell to auto and paracrine anabolic and catabolic pathway.
Export Options
About this article
Cite this article as:
Gentili Chiara and Cancedda Ranieri, Cartilage and Bone Extracellular Matrix, Current Pharmaceutical Design 2009; 15 (12) . https://dx.doi.org/10.2174/138161209787846739
DOI https://dx.doi.org/10.2174/138161209787846739 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Immunomodulatory Effect of Cytokines in the Differentiation of Mesenchymal Stem Cells: A Review
Current Stem Cell Research & Therapy A Case Report of Chordoma Presenting as a Sphenoid Sinus Mass: A Diagnostic Challenge
Current Medical Imaging Recent Applications of Artificial Intelligence in Early Cancer Detection
Current Medicinal Chemistry Naturally Plant-Derived Compounds: Role in Bone Anabolism
Current Molecular Pharmacology miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Cordycepin Affects Multiple Apoptotic Pathways to Mediate Hepatocellular Carcinoma Cell Death
Anti-Cancer Agents in Medicinal Chemistry Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Cancer Metastasis as Disrupted Developmental Phenotype
Current Genomics Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics The Role of Imaging in Computer-Assisted Tumor Surgery of the Sacrum and Pelvis
Current Medical Imaging Clinical and Imaging Features of Tumors in the Scapula
Current Medical Imaging miRNAs in Bone Development
Current Genomics LncRNAs as Therapeutic Targets for Autophagy-involved Cardiovascular Diseases: A Review of Molecular Mechanism and T herapy Strategy
Current Medicinal Chemistry Targeting Trail Towards the Clinic
Current Drug Targets The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Molecular Signaling Pathways as Potential Therapeutic Targets in Osteosarcoma
Current Medicinal Chemistry The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design